AELIS FARMA SAS (AELIS.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:AELIS • FR0014007ZB4

1.375 EUR
-0.04 (-2.83%)
Last: Feb 9, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to AELIS. AELIS was compared to 81 industry peers in the Biotechnology industry. Both the profitability and financial health of AELIS have multiple concerns. While showing a medium growth rate, AELIS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year AELIS has reported negative net income.
  • AELIS had a negative operating cash flow in the past year.
  • In the past 5 years AELIS reported 4 times negative net income.
  • AELIS had negative operating cash flow in 4 of the past 5 years.
AELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFAELIS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

1.2 Ratios

  • AELIS's Return On Assets of -52.61% is on the low side compared to the rest of the industry. AELIS is outperformed by 66.67% of its industry peers.
  • The Return On Equity of AELIS (-134.05%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROIC N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AELIS.PA Yearly ROA, ROE, ROICAELIS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • AELIS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AELIS.PA Yearly Profit, Operating, Gross MarginsAELIS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • AELIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AELIS has been increased compared to 1 year ago.
  • Compared to 5 years ago, AELIS has more shares outstanding
  • Compared to 1 year ago, AELIS has a worse debt to assets ratio.
AELIS.PA Yearly Shares OutstandingAELIS.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
AELIS.PA Yearly Total Debt VS Total AssetsAELIS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • AELIS has a Debt/Equity ratio of 0.74. This is a neutral value indicating AELIS is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.74, AELIS perfoms like the industry average, outperforming 48.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC7.48%
AELIS.PA Yearly LT Debt VS Equity VS FCFAELIS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • AELIS has a Current Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.18, AELIS is in the better half of the industry, outperforming 65.43% of the companies in the same industry.
  • AELIS has a Quick Ratio of 3.18. This indicates that AELIS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 3.18, AELIS is doing good in the industry, outperforming 69.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
AELIS.PA Yearly Current Assets VS Current LiabilitesAELIS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for AELIS have decreased strongly by -13.00% in the last year.
  • The Revenue for AELIS has decreased by -94.09% in the past year. This is quite bad
  • AELIS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -33.42% yearly.
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • AELIS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 146.58% yearly.
  • The Revenue is expected to grow by 88.24% on average over the next years. This is a very strong growth
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AELIS.PA Yearly Revenue VS EstimatesAELIS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
AELIS.PA Yearly EPS VS EstimatesAELIS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • AELIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 7.85, the valuation of AELIS can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, AELIS is valued cheaply inside the industry as 98.77% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of AELIS to the average of the S&P500 Index (27.86), we can say AELIS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 7.85
AELIS.PA Price Earnings VS Forward Price EarningsAELIS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AELIS.PA Per share dataAELIS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AELIS's earnings are expected to grow with 146.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.14%
EPS Next 3Y146.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • AELIS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AELIS FARMA SAS

EPA:AELIS (2/9/2026, 7:00:00 PM)

1.375

-0.04 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners25.12%
Inst Owner ChangeN/A
Ins Owners17.74%
Ins Owner ChangeN/A
Market Cap18.85M
Revenue(TTM)446.00K
Net Income(TTM)-8.20M
Analysts84.44
Price Target11.22 (716%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.85
P/S 42.27
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.18
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)0.18
Fwd EY12.73%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.03
BVpS0.45
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.61%
ROE -134.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.08%
ROA(5y)-24.2%
ROE(3y)-61.94%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.44%
Cap/Sales 6.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z N/A
F-Score2
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)106.33%
Cap/Depr(5y)205.47%
Cap/Sales(3y)3.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.8%
EPS Next Y-131.58%
EPS Next 2Y70.14%
EPS Next 3Y146.58%
EPS Next 5YN/A
Revenue 1Y (TTM)-94.09%
Revenue growth 3Y-33.42%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-52.86%
Revenue Next 2Y33.1%
Revenue Next 3Y88.24%
Revenue Next 5YN/A
EBIT growth 1Y-6.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-114.29%
EBIT Next 3Y152.58%
EBIT Next 5YN/A
FCF growth 1Y40.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.71%
OCF growth 3YN/A
OCF growth 5YN/A

AELIS FARMA SAS / AELIS.PA FAQ

What is the fundamental rating for AELIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to AELIS.PA.


Can you provide the valuation status for AELIS FARMA SAS?

ChartMill assigns a valuation rating of 3 / 10 to AELIS FARMA SAS (AELIS.PA). This can be considered as Overvalued.


What is the profitability of AELIS stock?

AELIS FARMA SAS (AELIS.PA) has a profitability rating of 0 / 10.


What is the expected EPS growth for AELIS FARMA SAS (AELIS.PA) stock?

The Earnings per Share (EPS) of AELIS FARMA SAS (AELIS.PA) is expected to decline by -131.58% in the next year.